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Human multipotent stem cell lines are ofgreat interest for studies ofhematopoi-
etic differentiation and maturation and ofleukemogenesis. The advent ofdifferent
stem cell assays (1-3) and the availability ofrecombinant or highly purified growth
factors (4-7) made possible the identification of precursor cells and delineation of
their growth factor dependency. Acute leukemias, which are believed to represent
clonal expansions ofnormally occurringprogenitorcells, haveproved useful in defining
different stages of normal differentiation (8). The use of such cells to study early
events ofstem celldifferentiation and maturation and to elucidate interlineage rela-
tionships has been limited by the lack of differentiation capacity in most leukemic
cells. Recently, a TALL and a T-cell lymphoblastic lymphoma with in vivo and/or
in vitro multilineage differentiation potential have been described that might serve
as models to study hematopoietic stem cells. The TALL displayed in vitro and in
vivo spontaneous and growth factor induced multilineage differentiation potential
(9, 10), while thelymphoblastic lymphoma showed conversion to a bilineage Tlym-
phoid and myeloid leukemia at relapse (11). Both lymphoblastic processes displayed
T cell precursor phenotypes of early thymocytes (CD2+ CD3- CD5+ CD7') or of
prothymocytes (CD2 - CD3-CD5`CD7'HLADR+TdT+) (12-14). These studies led
to the hypothesis that CD3 - CD4- CD7 + CD8 - precursor TALLs may represent
malignant counterparts of a multilineage stem cell (15).
In this manuscript we report a TALL with a more mature T lymphocyte pheno-
type (CD2+CD3*CD5+CD7''WT31+) than those previously reported, which also
has the capability ofmultilineage differentiation and maturation in the presence of
recombinant human growth factors. In the presence of granulocyte/macrophage
colony-stimulating factor (GM-CSF)' and IL-3, the leukemic cells gave rise to ter-
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minally differentiated functionally active segmented neutrophils. In the presence
of IL-2, leukemic cytotoxic T lymphocytes with MHC nonrestricted cytotoxicity
were derived. In the absence of any growth factor, a cell line with an immature blast
morphology and mixed lineage phenotype was established. The derivation of these
different leukemic cultures from the same malignant clone was unambiguously demon-
strated by unique monoclonal rearrangements of the constant region of the TCRS
gene and of the joining regions of the TCR(3, --y and -S genes.
Materials and Methods
Clinical Course ofthe Patient.
￿
A 25-year-old Caucasian male (MT) presented with multiple
petechiae, conjunctival hemorrhage, hepatosplenomegaly, and an anterior mediastinal mass
in March 1987. The white blood cell count(WBC) was 759,000/,,1, with 99% lymphoblasts.
A bone marrow aspirate showed infiltration with atypical CD2' and TdT+ and CD4- and
CD8- lymphoblasts. After polychemotherapy, the patient achieved a complete remission
lasting 5 mo. At first relapse, the bone marrow showed infiltration by lymphoblasts displaying
the same immunophenotype as at diagnosis. With reinduction therapy, the patient achieved
a short, unsustained remission. At three different time points during second relapse, leu-
kemic cells were obtained for the present studies. The patient died one year afterdiagnosis.
Leukemic Cells.
￿
PBMC were isolated by centrifugation through a Ficoll-Hypaque density
gradient. The fresh leukemic cells were either immediately processed for cell culture, im-
munophenotyping by flow cytometry, or frozen in RPMI 1640 tissue culture medium (Gibco
Laboratories, Grand Island, NY) with 10% heat-inactivated FCS (Gibco Laboratories) and
10% DMSO (Sigma Chemical Co., St. Louis, MO) and stored at -196°C .
Cell Culture.
￿
Fresh leukemic cells were set up in 24-well tissue culture plates (Costar, Cam-
bridge, MA) at a concentration of 106 cells/ml in Iscove's modified Dulbecco's medium
(IMDM) (Gibco Laboratories) supplemented with 20% FCS (HyClone Laboratories, Inc.,
Logan, UT), 2 MM L-glutamine (Gibco Laboratories), 100 U/ml penicillin, 100 ,g/ml strep-
tomycin (Gibco Laboratories), 25 mM HEPES buffer (Sigma Chemical Co.), 2 g/liter
NaHC03 in a humidified 5% COs, 95% ambient air atmosphere at 37°C. Recombinant
human growth factors were added to the cell cultures at the following concentrations: IL-2
(Amgen Biologicals, Thousand Oaks, CA), 100 U/ml; GM-CSF (Genetics Institute, Cam-
bridge, MA), 50 ng/ml during the first 3 wk, 10 ng/ml subsequently; IL-3 (Genetics Insti-
tutes), 10 U/ml (1 U/ml is defined as the amount of IL-3 that induces a half-maximal
[3H]thymidine incorporation in chronic myelogenous cells in vitro). Control cells were cul-
tured without growth factor as a control. The cultures were fed twice a week with freshmedium
and growth factors. IL-2-dependent and GM-CSFdependent leukemic cells were established
from these cultures. Cells from the GM-CSF leukemic cell cultures were subcloned by lim-
itingdilution, as described before (16). Cells were plated in 96-well microtiter plates at con-
centrations of 0.4, 1, 3, 10 cells per well in the presence of 50 ng/ml GM-CSF. A control
platecontaining no GM-CSF yielded no clones. The leukemic cells grown in IL-3 were weaned
from IL-3 after 10 wk in culture and a growth factor-independent leukemic cell culture was
established.
Morphological and Cytochemical Characteristics.
￿
Differential counts were performed on Wright's
Giemsa-stained smears of the fresh leukemic cells, from which the different cultures were
established, and on cytospins prepared from IL-3, GM-CSF, IL-2-dependent, and growth
factor-independent leukemic cell cultures. Cytochemical stains included staining for my-
eloperoxidase (MPO), periodic acid-Schiff(PAS), a-naphthyl butyrate esterase (nonspecific
esterase, NSE), Sudan Black(SB) and toluidine blue. Terminal deoxynucleotidyl transferase
(TdT) activity was determined by immunofluorescence usinga rabbit antiTdT mAb and
a fluorescein isothiocyanate conjugated goat anti-rabbit IgG (TdT iF Kit; Super Tech Inc.,
Bethesda, MD). 200 cells were evaluated under an immunofluorescence and phase contrast
microscope (Carl Zeiss, Inc., Thornwood, NY).
Immunophenotype.
￿
The expression of surface membrane antigens on fresh and cultured
leukemic cells was determined on an Ortho Spectrum III cytofluorograf (Ortho DiagnosticGRIESINGER ET AL.
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List ofMonoclonal Antibodies
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List of the mAbs used in this study according to the CD classification, where available. In other cases,
the antigen detected by the mAb is given.
' u, Unconjugated.
z University of Minnesota, Minneapolis, MN .
3 Duke University Medical Center, Durham, NC.
II Hayashibara Biochemical Laboratories, Inc., Okayama, Japan.
Institute Gustav-Roussy, Villejuif, France.
"nd, Not designated.
Systems Inc., Raritan, NJ) or a FAGS IV (Becton Dickinson & Co., Mountain View, CA)
using unconjugated (for indirect immunofluorescence) and FITC-orphycoerythrin(PE)-con-
jugated mAbs (Table I). For indirect immunofluorescence, 106 cells were suspended in 250 pl
fluorescence buffer (PBS, 4% newborn calfserum(Gibco Laboratories), 0.1% sodium azide),
Cluster
designation
Monoclonal
antibody Conjugate Supplier Antigen/specificity
CDl OKT 6 u' Ortho Diagnostic Cortical thymocyte
CD2 13133 u D. A. Vallerat Sheep erythrocyte receptor
CD3 OKT 3 u Ortho Diagnostic Mature T cell antigen
Leu-4 PE Becton Dickinson & Co. associated with TCR
CD4 Leu-3 u, FITC Becton Dickinson & Co. T cell helper/inducer
CD5 T101 u Hybritech, Inc., Pan-T lymphocyte
San Diego, CA
CD7 3A-1 u B. Haynes$ Pan-T lymphocyte
G3.7 u Oncogene Science, Inc.,
Mineola, NY
Leu-9 PE Becton Dickinson & Co.
CD8 OKT 8 u Ortho Pharmaceuticals T cell suppressor/cytotoxic
Leu-2 FITC Becton Dickinson & Co.
CD9 BA-2 u T. W. LeBlenl Lymphoid and myeloid
precursor-associated
antigen
CD10 BA-3 u T. W. LeBienl cALLA
J5 PE Coulter Immunology
CD13 MCS-2 u J . Minowadal Pan-myelomonocytic
antigen
CD14 MY 3 u Coulter Immunology Pan-monocytic antigen
CD16 Leu-11 FITC Becton Dickinson & Co. Fcy-receptor
CD19 B43 u F. Uckunl Pan-B
Leu-12 PE, FITC Becton Dickinson & Co.
CD24 BA-1 u T. W. LeBienl Pan-B
CD33 MY 9 u, PE Coulter Immunology Myeloid precursor antigen
CD34 MY 10 u Coulter Immunology Hematopoietic precursor
antigen
nd MY 8 u Coulter Immunology Myeloid lineage cells
nd Leu-7 FITC Becton Dickinson & Co. NK cells
nd Leu-19 PE Becton Dickinson & Co, NK cells
nd Anti-TCR-1 FITC Becton Dickinson & Co. TCR cx/$ framework
nd BTCS-1 FITC T Cell Sciences, Inc., Subpopulation of
Cambridge, MA TCR-y/b lymphocytes
nd TiTA u T. Hercendl Subgroup of TCR-y/b
lymphocytes expressing
Vy9Jy1.21104
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and stained with a predetermined concentration of mAb. Control ascites protein served as
a negative control. Cells were washed twice with fluorescence buffer and subsequently in-
cubated with a mixture of FITC-conjugated goat anti-mouse IgG and IgM. After three ad-
ditional washes in fluorescence buffer, cells were fixedin 1 % paraformaldehyde and analyzed.
Two-color fluorescence studies were carried out in 250 wl incubation volume with directly
PE- and FITC-conjugated mAbs following the manufacturers' instructions. Isotype-matched,
directly conjugated antibodies served as controls. All staining and washing steps were carried
out at VC.
Functional Studies.
￿
NK and LAK activity of IL-2- and GM-CSFdependent, and the growth
factor-independent, leukemic cell cultures were assessed as previously described (17). Pe-
ripheral blood lymphocytes obtained from normal donors were cultured for 14 d in IL-2 and
served as controls. Briefly, NK-sensitive K562 and NK-resistant HL-60 were labeled with
250-750 ACi of Na51CrO4 (5,000 p,Ci/ml; New England Nuclear, Boston, MA), for 60-90
min at 37oC. Cells were washed once in RPMI 1640 supplemented with 6% pooled human
serum and resuspended in culture medium and incubated at room temperature for 60 min.
Cells were then washed twice, resuspended in fresh medium, and 500 cells/well were added
to effector cells in 96-well V-bottomed multititerplates (Costar). E/T ratios ranged from 30:1
to 0.1 :1 . Plates were centrifuged at 65 g for 5 min and incubated in 5% C02 at 37°C for
4 h, afterwhich 150 pl ofthe supernatant was harvested from each well. Radioactivity released
in the supernatant was counted in a liquid scintillation counter (LKB 1216) and percent cyto-
toxicity was determined as follows: Percent cytotoxicity = 100 x [(experimental mean cpm
- spontaneous release mean cpm)/(maximal mean cpm - spontaneous mean cpm)].
The ability of cells to produce oxygen radicals in response to stimuli was assessed by the
reduction ofnitroblue tetrazolium (NBT; Sigma Chemical Co.) as previously described (18).
Briefly, 4 x 105 cells were incubated with 10 lAg/ml NBT for 20 min at 37'C and cytospin
Wright, Giemsa preparations were counted to determine the number ofcells containing blue-
black formazan deposits. NBT reduction was measured in unstimulated cells as well as in
those stimulated by PMA (5 ng/ml; Sigma Chemical Co.) and the synthetic chemotactic pep-
tide FMLP (Calbiochem-Behring Corp., La Jolla, CA) at a concentration of 10' M.
Ultrastructural Studies.
￿
Ultrastructural localization of MPO and platelet peroxidase was
performed according to the methods of Graham and Karnovsky (19) and Breton-Gorius et
al. (20) . Cells were fixed for 30 min at VC and subsequently incubated at room temperature
in a buffered diaminobenzidine/hydrogen peroxide solution for 60 min. Control cells were
incubated in a solution lacking the hydrogen peroxide. Detection of lymphocyte parallel tubular
arrays was performed as described before (21).
Cytogenetic Studies.
￿
Metaphase chromosome spreads were obtained from the GM-CSF
the IL-3, and the growth factor-independent leukemic cell cultures usingstandard methods.
Briefly, 0.5 x 106 and 1.0 x 106 cultured cells were harvested directly usingtwo techniques.
In the first, the cells were exposed to a mixture of0.075 M KCl (9 ml), 0.25% Trypsin-EDTA
(1 ml), and colcemid (701.1; final concentration, 0.07 kg/ml) at 37oC for 20 min. In the second,
the cells were suspended in 10 ml RPMI 1640 medium supplemented with 2070 FCS and
L-glutamine (29 mg/ml), exposed to colcemid (0.07 ug/ml) for 20 min at 37oC, and then
resuspended in 0.075 M KCl for 12 min at 37oC. Cells from both preparations were fixed
in 3 :1 methanol/glacial acetic acid, and slides were made in the usual fashion. Chromosomes
were G-banded using the Wright's technique of Sanchez et al. (22). A total of 10 metaphase
cells from each of the original cultures were fully analyzed, and a minimum of two photo-
graphic karyotypes were constructed for each abnormal clone. Karyotypes were designated
according to the ISCN 1985 (23).
DNA Extraction.
￿
High molecular weight DNA was extracted from fresh and cultured leu-
kemic cells by proteinase K digestion in TE, NaCl 0.1 M, 1% SDS, followed by two phenol/
chloroform/isoamyl alcohol (25:24:1) and two chloroform/isoamyl alcohol (24:1) extractions.
DNA was precipitated with absolute ethanol, dried, and resuspended in TE pH 7.4.
Detection of Gene Rearrangement.
￿
High molecular weight DNA was digested to completion
with Barn HI, Eco RI, or Xba I (Bethesda Research Laboratories, Gaithersburg, MD), size
fractionated on a 0.8% agarose gel, and transferred to a nylon membrane (Nytran; Schleicher
& Schuell, Inc., Keene, NH) in IOX SSPE. After washing and baking, the membrane wasGRIESINGER ET AL.
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prehybridized for 2-12 h and hybridized for 20 h at 42°C according to the manufacturer's
instructions. Probes were labeled to high specific activity by the random primer method (24).
After hybridization, membranes were washed two times for 15 min with 6 x SSPE, 0.1%
SDS at room temperature, two times for 15 min with 1 x SSPE, 0.5% SDS at 37 °C and
finally with 0.1 x SSPE, 1% SDS at 60 to 65°C for 30 min. Autoradiography was carried
out on Kodak XR film with two intensifying screens for 14-36 h at -70°C.
Probes.
￿
pb7 is a genomic 1 .6-kb Eco RI-Eco RI DNA probe that detects the humanTCRS
constant region. The probe was derived from a human chromosome 14 library with the mouse
TCRb constant region probe described by Chien et al. (25). Rearrangements of the TCR6
gene were detected using the cDNA probe 0/240-38 (26), kindly provided by M. S. Krangel
(Dana-Farber Cancer Institute, Boston, MA). This probe contains the Vb region, used in
the cell line IDP2, and the leukemic cell line PEER (26, 27), the Jbl region, and part of
the TCRb constant region (Cb). Rearrangements ofthe TCR0 were detected with a 770-bp
cDNA constant region probekindly provided by T W. Mak (University of Toronto, Toronto,
Ontario, Canada). Rearrangements of the TCRy gene were detected with a cDNA probe
pTyl kindly provided by R. Holcombe (Harvard University, Boston, MA) (28) detecting
the constant (Cy 1 and 2), joining regions (Jy 2.3 and 1.3), and a member ofthe V-YI family.
Rearrangements ofthe IgH chainjoining region were detected with a genomic 5.4-kbjoining
region probe(JH), kindly provided by S. Korsmeyer (Washington University, St. Louis, MO).
To detect rearrangements of the breakpointcluster region, the human bcr (Pr-1) (Oncogene
Science, Inc., Mineola, NY) probe was used. This is a 1.2-kb Hind III-Bgl II fragment of
genomic DNA that detects rearrangements of chromosome 22, resulting in formation of the
Philadelphia chromosome in patients with chronic myelogenous leukemia.
Results
EstablishmentofDierentLeukemic Cell Cultures with VariousGrowth Factorsfrom a Patient
with TALL. Fresh peripheral blood leukemic cellsof the patient obtained at second
relapse were cultured with no growth factor or in the presence ofhuman IL-3, GM-
CSF, or IL-2 . In the presence of IL-3 or GM-CSF, after a period of 6 and 10 wk,
respectively, proliferating cells began forming clumps and clusters and the cultures
could be expanded. Leukemic cells initially cultured in the presence of IL-3 were
weaned from this growth factor after 10 wk and have been in continuous culture
without the addition of any growth factor for 5 mo. In the presence of IL-2, the
fresh leukemic cells started to form clumps and clusters already after 24 h in culture
and have been in IL-2-dependent continuous culture for 5 mo. Control cultures without
growth factor showed no viable cells after 6 wk of culture. GM-CSFdependent cel-
lular subclones were obtained by limiting dilution from the GM-CSFdependent leu-
kemic cell cultures after 2 mo of continuous culture. Several GM-CSFdependent
cellular subclones were obtained, which all displayed the same phenotype as demon-
strated in Fig. 2, Tables II and III. These are designated GM-CSF dependent leu-
kemic cell lines, one of which is designated MN1.1.
Morphology andCytochemistry ofFresh andCulturedLeukemic Cells.
￿
Representative mor-
phologies ofuncultured and cultured leukemic cells are shown in Fig. 1 . A periph-
eral blood smear of fresh leukemic cells obtained at second relapse is shown in Fig.
1 A . Two small lymphoblasts with sparse, deeply basophilic cytoplasm and a high
nuclear/cytoplasm ratio were observed. The nuclei were irregular and convoluted
and displayed a rather dense, irregular chromatin structure with small nucleoli.
Cytochemical stains were negative for MPO and NSE, but generally positive for
TdT (Table II).
IL-3-cultured leukemic cells, GM-CSFcultured leukemic cells, and the GM-CSF1106
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TABLE II
Cytochemistry and Morphology of Fresh and Cultured Leukemic Cells
Staining for MPO, NSE, and TdT and differential count of uncultured (fresh)
peripheral blood leukemic blasts, from which the leukemic cell cultures were es-
tablished, the IL-3 or GM-CSF bulk cultures or the GM-CSF-dependent sub-
clone MN 1 .1, the growth factor-independent (leukemic cells initially cultured
in the presence ofIL-3 and subsequently weaned from this growth factor), and
the IL-2-dependent leukemic cells .
dependent cell line MN1.1 (Fig . 1 B) demonstrated the presence of all stages ofmy-
eloid differentiation (Table II) . Terminally differentiated neutrophils (72%), most
ofwhich were MPO+, along with a small percentage ofmonocytoid cells (6%) and
undiffentiated blasts (6%) were present . The extent of myeloid maturation in the
TABLE III
Immunophenotype of Fresh and Cultured Leukemic Cells
Phenotype of the uncultured (fresh) peripheral blood leukemic blasts, the IL-3,
or GM-CSF bulk cultures or the CM-CSF-dependent subclone MN 1 .1, the
growth factor-independent, and the IL-2-dependent leukemic cells . Results are
means obtained from two to five individual analyses . Immunophenotyping was
carried out according to Materials and Methods . WT31 is the anti-TCR-1 (Becton
Dickinson &Co .), anti-6 is the anti-S TCS-1 (T-Cell Science Inc .) mAb . NT,
not tested .
Cluster
designation/mAb Fresh
IL-3 or
GM-CSF
Growth factor
independent IL-2
CD2 92 7 94 98
CD3 96 3 97 89
CD4 7 60 0 0
CD5 94 NT 95 96
CD7 97 0 100 100
CD8 12 0 0 84
CD13 0 70 55 0
CD14 0 15 12 0
CD25 0 0 0 0
CD33 0 99 75 37
CD34 0 0 0 0
My8 0 85 0 0
WT31 25 0 36 84
Anti-S 0 0 0 0
Anti-TiyA 0 0 0 0
Leu-19 0 0 0 94
Cytochemistry/Morphology Fresh
IL-3 or
GM-CSF
Growth factor
independent IL-2
MPO 0 69 0 0
NSE 0 4 0 0
TdT 44 3 23 >90
Lymphoblasts 100 0 0 0
Undifferentiated blasts 0 6 100 0
Granulated lymphocytes 0 0 0 100
Myelocytes 0 16 0 0
Segmented granulocytes 0 72 10 0
Monocytoid cells 0 6 0 0GRIESINGER ET AL. 1107
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GM-CSFcultured leukemic cells was subject to some variation. Furthermore, the
degree of MPO expression as detected by cytochemical staining diminished with
time in culture. Ultrastructural studies, however, demonstrated that virtually 100%
ofGM-CSFcultured leukemic cells expressed highlevels ofMPO(datanot shown).
Growth factor-independent leukemic cells (Fig. 1 C) displayed size heterogeneity
and contained adeeply basophilic cytoplasm. The nuclei were of slightly irregular
shape, sometimes indented, and had a condensed chromatin structure and two or
morenucleoli. Mitoticfigureswere frequentlyseen. Cytochemical stains were nega-
tive for MPO, NSE (Table II), as well as SB and toluidine blue. 23% of the cells
expressed TdT. The lack of MPO expression was confirmed ultrastructurally.
IL-2-cultured leukemic cells (Fig. 1 D) contained a lightly basophilic cytoplasm,
azurophilic granules, and various degreesofvacuolization. Nuclei were ofirregular
shape, sometimes indented, and displayed up to four nucleoli. Cytochemically, all
the cells were negative for MPO, NSE, and weakly positive for TdT (Table II). No
parallel tubular arrays, typically seen in uncultured large granular lymphocytes (21),
were demonstrated ultrastructurally in the IL-2-dependent leukemic cell cultures.
However, they may be lost during in vitro culture (29).
Immunophenotype.
￿
The immunophenotypes ofthe freshandthe cultured leukemic
cells are shown in Table III. The fresh leukemic cells were strongly positive for the
T-lineage markers CD2, CD5, and CD7, as well as for the mature T lymphocyte
antigen CD3, a phenotype consistent with acute Tlymphoblastic leukemia. Only
25% of the fresh leukemic cells stained positive for WT31, which binds to the
CD3/TCR ado chain heterodimer complex(30, 31). However, therewas noevidence
forthe expression ofthe"second" TCR y/Schain heterodimer as assessed bystaining
with anti-S (antiTCS-1) and antiTiyA (32). The cells were negative for CD4 and
CD8 aswell asB-lymphoid (CD10, CD19, CD20, CD24), precursor-associated (CD9,
CD34), and myeloid antigens (CD13, CD14, MY 8, and CD33) (Fig. 2 A).
A high percentage of the IL-3- and GM-CSF-cultured leukemic cells expressed
CD33 (Fig. 2 B), CD13, and MY8 (33). Tlineage markers (CD2, CD3, CD7) were
expressedby alow percentage ofcells inthis culture. This phenotypewasconsistent
with the myeloid morphology of cells grown under these conditions.
The growth factor-independent leukemic cell cultures displayed a mixed pheno-
type coexpressing Tlineage (CD2, CD3, CD7) and myeloid (CD13 and CD33) an-
tigens. Two-color fluorescence demonstrated coexpression ofCD7 andCD33 by 73.6%
oftheculturedleukemic cells(Fig. 2 C). Only 36% expressedWT31, theywerenegative
for CD4, CD8, anti-6 (antiTCS-1), and antiTiyA. This pattern ofTcell antigen
expression was very similar to that of the fresh leukemic cells.
The IL-2-culturedleukemic cellswere positive forCD2, CD7, and theCD3/TCR
a/(3 complex (WT31+). Additionally, they expressed the T suppressor/cytotoxic-as-
sociated antigen CD8, and Leu-19, which is characteristically found on fresh periph-
eral blood NK cells and can be acquired by normal peripheral blood lymphocytes
when cultured in the presence ofIL-2. Suprisingly, 37% o£the cells expressed the
myeloid precursor-associated antigen CD33 (Fig. 2 D).
Genotype.
￿
The clonal relationship of the fresh leukemic and cultured cells was
addressed subsequently. Fig. 3 A-C, shows representative Southern blots ofthe IL-
3-culturedleukemiccells(lane 1), fresh leukemic cells obtainedfromperipheral blood
during second relapse (lane 2), germline source (lane 3), and IL-2-dependent leu-GRIESINGER ET AL .
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FIGURE 2 .
￿
Expression ofCD3 andCD33 on uncultured leukemic cells (A), andCD7 andCD33
on GM-CSFdependent leukemic cellular subclone MN-1 .1 (B), growth factor-independent (C),
and IL-2-dependent leukemic cells (D) . For each sample, forward and 90°C scatter profile of
gated cells are shown on a linear scale . The fluorescence intensity for FITC and PE is shown
on a logarithmic scale, the lowest contour level was three cells. Percentages of cells in each quad-
rant are given . Staining and selection of controls was performed as outlined in Materials and
Methods .
kemic cells (lane 4) . Both the fresh and the IL-3-cultured leukemic cells displayed
identical unique 11 .5-kb Bam HI (Fig . 3 A) and 10.0-kb Xba I (Fig . 3 B) TCRS
constant region rearranged bandswith the p67 probe . A faint germline band in the
fresh leukemic sample was presumably due to the presence of nonleukemic cells .1110
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FIGURE 3 .
￿
Southern blot analysis IL-3
cultured (lane 1), uncultured (lane 2)
leukemic cells, and placenta (lane 3) .
High molecular weight DNA was
digested with Bam HI (A) and Xba I
(B andC) and probed with p67 (A and
B) andwith pTyl (C). Rearrangements
are marked with arrows, germline
bands with bars.
Identical unique rearrangements of the TCR-S constant region were observed in
growth factor-independent, GM-CSF and IL-2-dependent cell cultures (data not
shown) . The uncultured and all cultured cells displayed an identical 1.0-kb Eco RI
(Fig . 4 A) and 10-kb Bam HI (not shown) rearrangement of the JSl region . The
IL-3-cultured and fresh leukemic cells also displayed identical clonal rearrangements
of theTCRy chain gene (Fig . 3 C) . A single identicalTCR 0 chain gene rearrange-
ment was observed in uncultured, IL-2- and GM-CSFdependent, and growth
factor-independent leukemic cells, asshown in Fig . 4B. Theimmunoglobulin heavy
chain gene andthe break point clusterregion (bcr) were found in the germline configu-
ration in all cultured and the uncultured leukemic cells (data not shown) .
Thus, leukemic cells cultured under various conditions displayed morphological
features of at least two different lineages, but showed identical rearrangements of
FIGURE 4 .
￿
Southern blot analysis of IL-2-dependent
(lane 1), uncultured (lane 2), GM-CSFdependent (lane
3) leukemic cells, and placenta (lane 4) . High molec-
ular weight DNA was completely digested with EcoRI
(A) and Bam HI (B) and probed with theTCRScDNA
probe 0-240/38 (A)andtheTCR(3 probe T/3 (B) . Rear-
rangements are marked with arrows, germline bands
with bars .GRIESINGER ET AL.
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the TCR/3, -y, and -6 genes to the fresh leukemic cells. These data clearly demon-
strated that the fresh leukemic cells and the different leukemic cell cultures were
derived from the same malignant clone.
Karyotype.
￿
Cytogenic analyses ofthe GM-CSFdependent leukemic cell culture,
the IL-3-cultured leukemic cells, and the growth factor-independent leukemic cell
cultures identified six closely related abnormal clones. All had an interstitial dele-
tion ofpart of the long arm of chromosome 6 and a three-break translocation in-
volving the long arm ofchromosome 1 and short arms ofchromosomes 10 and 12
(Table IV). A G-banded karyotype ofone metaphase cell from the GM-CSF culture
demonstrating these abnormalities is shown in Fig. 5. These findings provided fur-
ther evidence that the cultured cells arose from a common malignant precursor.
Functional Studies.
￿
To determine the functional chraracteristics of the morpho-
logically terminallydifferentiated neutrophilic granulocytes ofthe GM-CSFcultured
cells, the oxygen radical production of either unstimulated or stimulated (PMA or
FMLP) cells was assessed by measuring the NBT reduction (Table V). Freshly ob-
tained peripheral blood granulocytes served as a positive control and the growth
factor-independent leukemic cell cultures as a negative control. 20% ofPMA, but
none ofthe FMLP-stimulated GM-CSFculturedleukemiccells reduced NBT. Growth
factor independent leukemic cell cultures displayed no oxygen radical synthesis in
response to stimuli.
Since IL-2-dependent leukemic cells expressed a phenotype similar to cytotoxic
lymphocytes (see Table III), NK and LAK activity were tested. In a chromium-
release assay, the IL-2-dependent leukemic cells exerteda high lytic activity against
both the NK-sensitive K562 and the NK-resistant HL-60 targets, while the myeloid
GM-CSF-dependent and the undifferentiated growth factor-independent leukemic
cells were devoid of lytic activity against either target cell line (Fig. 6).
TABLE IV
Cytogenetic Studies of Cultured Leukemic Cells
(g25;pl3 ;p13)
Cultures
Number
metaphases
Total
of
analyzed
Per clone G-banded karyotypes
Growth factor independent 10 7 47, XY,+19, del (6)(gl5g25), t(1 ;10;12)(g25;pl3;pl3)
2 47, XY, + 19, del (6)(g15q25), dir dup (I7)(g11 .2->q23),
t(1 ;10;12)(g25 ;p13 ;pl3)
48,XY, + 19, del (6)(g15q25), +del (6)(g15q25),
t(1 ;10;12)(g25 ;pl3 ;p13)
GM-CSF 10 2 48, XY, + 17, + del (6)(g15q25),
t(1 ;10 ;12)(g25;p13 ;p13)
8 49, XY, -7, +13, +19, +del (6)(g15q25), t(1 ;10;12)
(g25 ;p13 ;p13), +der (7) t (7;17)(836;21)
IL-3 10 5 47, XY, + 19, del (6)(gl5q25), t(1 ;10 ;12)(g25 ;p13 ;p13)
2 48, XY, + 19, del (6)(g15g25), +del(6)(gI5q25),
t(1 ;10;12)(g25;p13;p13)
3 49, XY, + 17, + 19, + del (6)(g15q25), t(1 ;10;12)1112
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TABLE V
Oxygen Radical Production of Cultured Leukernic Cells
Oxygen radical production was assessed by measuring the reduction of NBT
in unstimulated or PMA (5 ng/ml) or FMLP (10-7 M) -stimulated cells . Cells
were stained with Wright-Giemsa and scored for black-blue formazan deposits .
ControlPMN, polymorphonuclear cells from a healthy donor ; GM-CSF, GM-
CSF-dependent leukemic cell culture .
FIGURE 6 .
￿
Percent cytotoxicity of the IL-2-
dependent leukemic cell culture (IL-2), the
GM-CSFdependent cell culture (GM-CSF),
and the growth factor-independent leukemic
cell culture (GFindependent) against the NK-
sensitive target cell line K562 and the NK-
resistant target cell line HL-60 in a chromium-
release assay. Mean values of triplicates are
given, SEM was<5%. Representative data of
one experiment which were reproduced in two
additional experiments are shown .
Discussion
Multilineage Differentiation Potential ofMT-ALL.
￿
To the knowledge of the authors,
this is the first report ofa mature predominantly CD3+ WT31+ TALL with mul-
tilineage differentiation potential . At presentation, the leukemic cells displayed the
typical morphological and cytochemical characteristics of an acute lymphoblastic
leukemia and predominantly expressed a phenotype consistent with mature CD3+
TCR-ac//3-expressing T lymphocytes (30-32). This mature phenotype was in con-
trast to the immature phenotype of the previously reported multipotential TALL
DU.528 (9, 10) and theTlymphoblastic lymphoma (11), whichexpressedCD2, CD5,
andCD7 (consistent with an early thymocyte) and CD7, HLADR, andTdT (con-
sistent withaprothymocyte) (12-14) respectively. Theuncultured tumor cells of these
patients didnot express aCD3/TCR complexon the cell surface (9-11) . Our studies
demonstrate by morphological, phenotypic, and functional criteria, multilineage
differentiation of leukemic MT-ALL blasts . Three different leukemic cell cultures
were derived from the original leukemic blasts :
(a) Myeloid and monocytic cells ofvarious differentiation stages including termi-
nally differentiated functional neutrophilic granulocytes arose in the presence ofIL-
3 and GM-CSF. In contrast to the DU.528 cell line (9, 10), no erythroid cells,
megakaryocytes, eosinophils, or basophils were observed in these cultures .
(b) Mixed lineage cells in those cultures, that were started with IL-3 and subse-
quently weaned from this growth factor, displayed an undifferentiated blast mor-
Stimulus Control PMN GM-CSF
Growth factor
independent
None 12 0 0
PMA 90 20 0
FMLP 90 0 01114
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phology andcoexpressed Tlineage-associated antigens (CD2,CD3,CD7,WT31) with
the panmyeloid antigen CD13, and the early myeloid antigen CD33, which is ex-
pressed on a subset of CFU-GEMM, BFU-E, and CFU-GM and their progeny
(reviewed in reference 33).
(c) Granulated lymphocytes developed in the presence ofIL-2 with characteristic
morphological (azurophilic granules), phenotypic (acquisition ofCD8 and Leu-19),
and functional features (NKand LAK activity) ofMHC-unrestricted cytotoxic lym-
phocytes (34). Strikingly, coexpression oftheT cell antigens CD2,CD3,CD5,CD7,CD8,
WT31 together with the CD33 antigen was observedin theIL-2-dependent leukemic
cultures.
Althoughcoexpression ofmyeloid and lymphoid, as wellasT and B cell antigens,
has been observed in a small percentage of acute leukemias (35), coexpression of
the mature T lymphocyte antigen CD3 andWT31 in associationwith the immature
myeloid antigens CD33 and CD13 has not been reported to our knowledge. The
possibility that this process represented a rare T cell blast crisis ofa chronic myelog-
enous leukemia was essentially ruled out by the lack of cytogenetic or molecular
evidence (bcr rearrangement) ofPhiladephia chromosome formation. Two alterna-
tive hypotheses for the coexpression of antigens that are normally found on cells
belonging to different lineages have been proposed : Normal precursor cells at early
stages ofdifferentiation and before definite commitment to a specific lineage may
display a certain degree of"lineage promiscuity" (8) with coexpression ofantigens
associated with different lineages. Thus, a differentiation event normally occurring
in afew precursors may be immortalized by malignant transformation and become
detectable after clonal expansion. The expression ofmature T cell antigens (CD3,
WT31) with immature myeloid antigens (CD33 and/or CD13) in the present case,
however, is more consistent with the concept of "lineage infidelity" as proposed by
Smith et al. (36). They suggest that transformational events in leukemias may be
associatedwith aberrant geneticprogramming and theexpression of"inappropriate"
gene products. However, it iscurrentlyunknownwhetheranormal counterpartbearing
this mixed lineage phenotype exists. Our results therefore warrant further studies
to search for coexpression of antigens associated to the T lymphocyte and the my-
eloid lineages in nonleukemic cells.
Genotypic and Cytogenetic Evidencefor the Derivation ofCultured and Uncultured Leukemic
Cellsfrom theSame Malignant Clone. UniqueTCR-S, -(3, and --y generearrangements
unambiguously proved that the uncultured and the various cultured leukemic cells
displayingcharacteristics associated to differentlineageswere derived from the same
malignant clone.
Recently, the human TCRS gene, which encodes a protein that is expressed as
a heterodimer with the protein product ofthe TCR,y gene, has been identified and
characterized (25-27, 37-41). Identical unique monoallelic rearrangements of the
TCRS constant region were detected in all cultured and the uncultured leukemic
cells. A restriction fragment length polymorphism was ruled out by use ofdifferent
restriction enzymes for this analysis and by demonstration of a germline band in
contaminating nonleukemic cells of the patient. The rearrangement of the TCR-S
constant region detected byconventional Southern analysisafter Barn HI andXbaI
digests may be due to recombinatorial events involving TCRaJ regions 3' of the
TCR-S region as described in RPMI 8402 (40). Additional Southern analysis re-GRIESINGER ET AL.
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vealed an identical monoallelic rearrangement of the TCR6J1 region . The reper-
toire oftheTCR6 gene rearrangements is currently unknown. However, the 1.0-kb
Eco RI/12.0-kb Bam HI rearrangement ofMT-ALL was detected in only 3 of 100
leukemias and cell lines studied (Griesinger, F., submitted forpublication). This es-
sentially rules out the possibility that thisJ61 rearrangement was fortuitously iden-
tical in the different MT-ALL cultures studied. An identical monoallelic rearrange-
mentoftheTCR/3 geneandbiallelicrearrangements ofthe TCRy genein all cultured
and the uncultured leukemic cells provided further prooffor their clonal identity.
The molecular genetic findings of derivation from a single clone were consistent
with the cytogenetic results obtained from the IL-3- and GM-CSFdependent, as
well as the growth factor-independent leukemic cells.
Induction ofProliferation andDifferentiation ofLeukemic Cellsby Recombinant Human Growth
Factors. Leukemic cells in thesestudiesresponded to different recombinant physio-
logical growth factors with proliferation and ordered differentiation. However, the
question ofwhich subset ofleukemic cells was capable ofin vitrodifferentiation and/or
whether the different leukemic cultures were the result of the growth of minor leu-
kemic populations remains to be addressed.
IL-3 and GM-CSF are involved in the regulation ofproliferation and differentia-
tion of normal and leukemic myeloid precursor cells (4-7, 42-51). Some effects of
IL-3 and GM-CSF on murine nonleukemic T and B cell precursors have been pro-
posed (52, 53). Recently, aGM-CSF and IL-3-dependent precursorTcell leukemic
cell line TALL 101 has been described (54), which did not, however, show evidence
ofmyeloid differentiation or maturation. Intheleukemic cell cultures describedherein,
differentiation and maturation along the myeloid cell lineage occurred only in the
presence ofIL-3 and GM-CSF, but not in the presence ofIL-2. These data suggest
that leukemic cells derived from the malignant clone and apparently committed to
T cell differentiation were susceptible to IL-3 and GM-CSF and responded with
a genetic program similar to normal hematopoietic precursor cells. In contrast to
the DU-528 cell line, erythroid, megakaryocytic, basophilic, and mast cell elements
(10) were absent in the IL-3 and GM-CSF cultures of MT-ALL. This suggests a
restricted differentiation potential ofthis leukemia or, alternatively, the requirement
ofadditional factors for multilineage differentiation that may be provided by 5637-
conditioned medium used in the DU.528 cultures.
IL-2 stimulates T cell differentiation and proliferation and induces cytotoxic ac-
tivity in NK cells, Tlymphocytes, and some T cell leukemias (34, 55-62). MT-ALL
cultured in the presence ofIL-2 developed functional, morphological, and pheno-
typic features similar to non-MHC-restricted cytotoxic lymphocytes. This suggests
that a genetic program, similar to normal cytotoxic lymphocytes(34), was activated
in the leukemic cells by IL-2. To our knowledge, this is the first TALL to display
such IL-2-induced cytotoxic activity withoutthe morphological orphenotypic char-
acteristics of "LGU-leukemia (58) or of a "LAK cell precursor" ALL (62).
Although we were able to demonstrate the derivation of the IL-3-GM-CSF and
IL-2-dependent and the growth factor-independent leukemic cells from the same
malignant clone, the exact pathway of differentiation from the original fresh leu-
kemic cellsto the different leukemic cell cultures iscurrently unknown. It is possible
that undetectably small leukemic populationswith myeloid andcytotoxiccharacter-
istics obtained a proliferative advantage in vitro in the presence ofthe appropriate1116
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growth factor. Alternatively, cells with multilineage differentiation potential might
have differentiated into the described cells of the different cell lineages. Whether
such multilineage differentiation results from activation of normal genetic differen-
tiation programs or through abnormal programs marking leukemic transformation
remains an area of further studies.
Summary
We report an acute Tlymphoblastic leukemia with a predominantly mature
CD3+CD7 + WT31+ phenotype that was induced to differentiate into different cell
lineages by various recombinant human growth factors. In the presence of IL-3 or
GM-CSF, the leukemic cells gave rise to myeloid and monocytic cells including ter-
minally differentiated, partially functional, segmented neutrophilic granulocytes as
assessed by morphologic, cytochemical, immunophenotypic, and functional criteria.
In the presence of IL-2, leukemic granulated lymphoid cells exhibiting MHC-
unrestricted cytotoxicity and expressing a CD2+ CD3+CD5+ CD7+CD8+ CD33+
WT31 + Leu19+ phenotype arose. Leukemic cell cultures initiated with IL-3 yielded
growth factor-independent cells with a mixed lineage phenotype and morphologic
and cytochemical evidence of immature blasts . These were T lymphocyte and my-
eloid surface antigen (CD2,CD3,CD5,CD7,CD13,CD33,WT31) positive. Identical re-
arrangements of the constant region of the TCRS gene and of the joining regions
of the TCRR, -'Y, and -S genes were observed in the fresh and all cultured leukemic
cells, indicating that they were derived from the same malignant clone. Consistent
with the molecular genetic data, the cytogenetic analyses ofthe GM-CSF, IL-3-cul-
tured and the growth factor-independent leukemic cells showed the presence of mul-
tiple, closely related abnormal clones, all of which had an interstitial deletion ofpart
of the long arm of chromosome 6 and a complex 1 ;10;12 translocation.
In conclusion, these data demonstrate the involvement of a multipotent leukemic pre-
cursor cell in this predominantly mature CD2+CD3+CD5+CD7+WT31+ TALL.
This multipotent leukemic precursor may be susceptible to various growth factors
and respond with ordered differentiation and maturation.
The authors thank Barbara Streifel for her expert technical assistance in performing the
cytogenetic studies. The authors are indebted to Cindy Prange and Lia Gore for editorial
assistance.
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